Novartis's Onbrez Breezhaler approved in EU for COPD
This article was originally published in Scrip
Executive Summary
Novartis's bronchodilator Onbrez Breezhaler (indacaterol; formerly QAB149) has been approved in the EU as a once-daily maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, following a positive CHMP opinion in September.